Development of autotaxin inhibitors: A series of tetrazole cinnamides.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 01 2021
Historique:
received: 15 09 2020
accepted: 28 10 2020
pubmed: 8 11 2020
medline: 23 7 2021
entrez: 7 11 2020
Statut: ppublish

Résumé

A series of inhibitors of Autotaxin (ATX) have been developed from a high throughput screening hit, 1a, which shows an alternative binding mode to known catalytic site inhibitors. Selectivity over the hERG channel and microsomal clearance were dependent on the lipophilicity of the compounds, and this was optimised by reduction of clogD whilst maintaining high affinity ATX inhibition. Compound 15a shows good oral exposure, and concentration dependent inhibition of formation of LPA in vivo, as shown in pharmacokinetic-pharmacodynamic (PK/PD) experiments.

Identifiants

pubmed: 33160025
pii: S0960-894X(20)30774-5
doi: 10.1016/j.bmcl.2020.127663
pii:
doi:

Substances chimiques

Amides 0
Cinnamates 0
Enzyme Inhibitors 0
Tetrazoles 0
cinnamic acid 140-10-3
Phosphoric Diester Hydrolases EC 3.1.4.-
alkylglycerophosphoethanolamine phosphodiesterase EC 3.1.4.39

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

127663

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Christopher G Thomson (CG)

Global Discovery Chemistry, Novartis Institutes For Biomedical Research, Horsham, UK. Electronic address: chris.thomson@pharmaron-uk.com.

Darren Le Grand (D)

Global Discovery Chemistry, Novartis Institutes For Biomedical Research, Horsham, UK.

Mark Dowling (M)

Respiratory Disease Area, Novartis Institutes For Biomedical Research, Horsham, UK.

David Beattie (D)

Global Discovery Chemistry, Novartis Institutes For Biomedical Research, Horsham, UK.

Lucy Elphick (L)

Respiratory Disease Area, Novartis Institutes For Biomedical Research, Horsham, UK.

Michael Faller (M)

Department of Chemical Biology and Therapeutics, Novartis Institutes For Biomedical Research, Basel, Switzerland.

Mark Freeman (M)

Respiratory Disease Area, Novartis Institutes For Biomedical Research, Horsham, UK.

Elizabeth Hardaker (E)

Respiratory Disease Area, Novartis Institutes For Biomedical Research, Horsham, UK.

Victoria Head (V)

Metabolism and Pharmacokinetics, Novartis Institutes For Biomedical Research, Horsham, UK.

Rene Hemmig (R)

Department of Chemical Biology and Therapeutics, Novartis Institutes For Biomedical Research, Basel, Switzerland.

Johan Hill (J)

Respiratory Disease Area, Novartis Institutes For Biomedical Research, Horsham, UK.

Andrew Lister (A)

Global Discovery Chemistry, Novartis Institutes For Biomedical Research, Horsham, UK.

David Pascoe (D)

Global Discovery Chemistry, Novartis Institutes For Biomedical Research, Horsham, UK.

Sebastien Rieffel (S)

Department of Chemical Biology and Therapeutics, Novartis Institutes For Biomedical Research, Basel, Switzerland.

Binesh Shrestha (B)

Department of Chemical Biology and Therapeutics, Novartis Institutes For Biomedical Research, Basel, Switzerland.

Oliver Steward (O)

Global Discovery Chemistry, Novartis Institutes For Biomedical Research, Horsham, UK.

Florence Zink (F)

Department of Chemical Biology and Therapeutics, Novartis Institutes For Biomedical Research, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH